Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies

Leukemia

Volumn 27, Issue 6, 2013, Pages 1263-1274

  Matlawska Wasowska, K ^a   Ward, E ^b   Stevens, S ^a,c   Wang, Y ^b   Herbst, R ^b   Winter, S S ^a   Wilson, B S ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b MEDIMMUNE   (United States)

^c LAWRENCE UNIVERSITY   (United States)

Author keywords

ADCC; ADCP; leukemia; monoclonal antibodies; pre B ALL; targeted therapies

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; MEDI 551; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DEPENDENT CELLULAR PHAGOCYTOSIS; ANTIGEN ANTIBODY COMPLEX; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL SURFACE; CHILD; CONTROLLED STUDY; EFFECTOR CELL; ENDOCYTOSIS; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL SYNAPSE; IN VITRO STUDY; LEUKEMIA CELL; MACROPHAGE; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHAGOCYTOSIS; PRE B LYMPHOCYTE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TARGET CELL; TREATMENT DURATION; TUMOR VOLUME; WEIGHT REDUCTION;

ACUTE DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD19; CELL LINE, TUMOR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FUCOSE; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, B-CELL; MACROPHAGES; MALE; MICE; MICE, SCID; TRANSPLANTATION, HETEROLOGOUS;

EID: 84878911052     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.5     Document Type: Article

References (52)

1. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008; 371: 1030-1043. (Pubitemid 351389536)
2. Malempati S, Gaynon PS, Sather H, La MK, Stork LC. Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: children's oncology group study CCG-1952. J Clin Oncol 2007; 25: 5800-5807.
3. Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol 2008; 20: 444-449.
4. Iida S, Kuni-Kamochi R, Mori K, Misaka H, Inoue M, Okazaki A et al. Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood. BMC Cancer 2009; 9: 58.
5. Munn DH, McBride M, Cheung NK. Role of low-affinity Fc receptors in antibodydependent tumor cell phagocytosis by human monocyte-derived macrophages. Cancer Res 1991; 51: 1117-1123.
6. Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 2008; 7: 2517-2527.
7. Bowles JA, Weiner GJ. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods 2005; 304: 88-99. (Pubitemid 41262223)
8. Siberil S, Dutertre CA, Fridman WH, Teillaud JL. FcgammaR: The key to optimize therapeutic antibodies? Crit Rev Oncol Hematol 2007; 62: 26-33. (Pubitemid 46343788)
9. McEarchern JA, Oflazoglu E, Francisco L, McDonagh CF, Gordon KA, Stone I et al. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood 2007; 109: 1185-1192. (Pubitemid 46220667)
10. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99: 754-758. (Pubitemid 34525533)
11. Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P et al. Rituximabdependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004; 64: 4664-4669. (Pubitemid 38856941)
12. Veeramani S, Wang SY, Dahle C, Blackwell S, Jacobus L, Knutson T et al. Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood 2011; 118: 3347-3349.
13. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22: 7359-7368.
14. Sato S, Ono N, Steeber DA, Pisetsky DS, Tedder TF. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J Immunol 1996; 157: 4371-4378. (Pubitemid 126449355)
15. Depoil D, Fleire S, Treanor BL, Weber M, Harwood NE, Marchbank KL et al. CD19 is essential for B cell activation by promoting B cell receptor-antigen microcluster formation in response to membrane-bound ligand. Nat Immunol 2008; 9: 63-72. (Pubitemid 350286205)
16. Otero DC, Rickert RC. CD19 function in early and late B cell development. II CD19 facilitates the pro-B/pre-B transition. J Immunol 2003; 171: 5921-5930. (Pubitemid 37467210)
17. Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res 2008; 68: 8049-8057.
18. Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson Jr DM et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood 2010; 115: 1204-1213.
19. Yazawa N, Hamaguchi Y, Poe JC, Tedder TF. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc Natl Acad Sci USA 2005; 102: 15178-15183. (Pubitemid 41513355)
20. Liu XY, Pop LM, Tsai L, Pop IV, Vitetta ES. Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines. Int J Cancer 2010; 129: 497-506.
21. Molhoj M, Crommer S, Brischwein K, Ran D, Sriskandarajah M, Hoffmann P et al. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. Mol Immunol 2007; 44: 1935-1943.
22. Herbst R, Wang Y, Gallagher S, Mittereder N, Kuta E, Damschroder M et al. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther 2010; 335: 213-222.
23. Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008; 20: 471-478.
24. Ward E, Mittereder N, Kuta E, Sims GP, Bowen MA, Dall'Acqua W et al. A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. Br J Haematol 2011; 155: 426-437.
25. Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res 2007; 67: 8882-8890. (Pubitemid 47437465)
26. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277: 26733-26740. (Pubitemid 34951677)
27. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8: 34-47.
28. Meng X, Matlawska-Wasowska K, Girodon F, Mazel T, Willman CL, Atlas S et al. GSI-I (Z-LLNle-CHO) inhibits gamma-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia. Leukemia 2011; 25: 1135-1146.
29. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997; 90: 1109-1114. (Pubitemid 27314146)
30. Otero DC, Omori SA, Rickert RC. Cd19-dependent activation of Akt kinase in B-lymphocytes. J Biol Chem 2001; 276: 1474-1478. (Pubitemid 32096580)
31. Sutton VR, Wowk ME, Cancilla M, Trapani JA. Caspase activation by granzyme B is indirect, and caspase autoprocessing requires the release of proapoptotic mitochondrial factors. Immunity 2003; 18: 319-329. (Pubitemid 36351513)
32. Voskoboinik I, Smyth MJ, Trapani JA. Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol 2006; 6: 940-952. (Pubitemid 44851736)
33. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004; 294: 15-22. (Pubitemid 39626587)
34. Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2011; 117: 2423-2432.
35. Lazar GA, Dang W, Karki S, Vafa O, Js Peng, Hyun L et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 2006; 103: 4005-4010.
36. Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S et al. Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization. Adv Enzyme Regul 2008; 48: 152-164.
37. Horton HM, Bernett MJ, Peipp M, Pong E, Karki S, Chu SY et al. Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies. Blood 116: 3004-3012.
38. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940-3947. (Pubitemid 46606207)
39. Zalevsky J, Leung IW, Karki S, Chu SY, Zhukovsky EA, Desjarlais JR et al. The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates. Blood 2009; 113: 3735-3743.
40. Cardarelli PM, Rao-Naik C, Chen S, Huang H, Pham A, Moldovan-Loomis MC et al. A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. Cancer Immunol Immunother 2010; 59: 257-265.
41. Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011; 186: 3762-3769.
42. Cherukuri A, Cheng PC, Pierce SK. The role of the CD19/CD21 complex in B cell processing and presentation of complement-tagged antigens. J Immunol 2001; 167: 163-172. (Pubitemid 32567774)
43. Sieber T, Schoeler D, Ringel F, Pascu M, Schriever F. Selective internalization of monoclonal antibodies by B-cell chronic lymphocytic leukaemia cells. Br J Haematol 2003; 121: 458-461. (Pubitemid 36628337)
44. Topham NJ, Hewitt EW. Natural killer cell cytotoxicity: how do they pull the trigger? Immunology 2009; 128: 7-15.
45. Krzewski K, Strominger JL. The killer's kiss: the many functions of NK cell immunological synapses. Curr Opin Cell Biol 2008; 20: 597-605.
46. Hatjiharissi E, Hansen M, Santos DD, Xu L, Leleu X, Dimmock EW et al. Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clin Lymphoma Myeloma 2007; 7: 286-290. (Pubitemid 46408193)
47. Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res 2011; 17: 6448-6458.
48. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009; 69: 4941-4944.
49. Borowitz MJ, Pullen DJ, Winick N, Martin PL, Bowman WP, Camitta B. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group. Cytometry B Clin Cytom 2005; 68: 18-24. (Pubitemid 41566359)
50. Leonard JP, Schuster SJ, Emmanouilides C, Couture F, Teoh N, wegener WA et al. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 2008; 113: 2714-2723.
51. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010; 142: 699-713.
52. Gluck WL, Hurst D, Yuen A, Levine AM, Dayton MA, Gockerman JP et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 2004; 10: 2253-2264. (Pubitemid 38445682)